Application for lateral flow test

Upfront Diagnostics has announced the publication of a landmark study demonstrating the development and successful clinical application of the world’s first lateral flow test capable of measuring Glial Fibrillary Acidic Protein (GFAP). This breakthrough represents a major leap forward in the rapid and accurate diagnosis of Traumatic Brain Injury (TBI).

The study, published in a leading scientific journal, highlights the unprecedented speed and accuracy of Upfront Diagnostics’ novel GFAP lateral flow device. GFAP, a protein released into the bloodstream following brain injury, has emerged as a key biomarker for TBI. Until now, GFAP measurement has required either complex laboratory-based assays or bulky point-of-care systems – neither of which are ideal for emergency settings.

 “We are incredibly proud to introduce the first rapid lateral flow GFAP test in history – this is a true game-changer for TBI diagnosis,”

said Dr. Joshua Bernstock, Chief Medical Officer at Upfront Diagnostics.

“This study validates our commitment to delivering cutting-edge solutions that directly improve patient outcomes. By enabling fast and reliable GFAP measurement at the point of care, we can empower healthcare professionals to make more informed decisions, potentially saving lives and reducing the long-term consequences of brain injury.”

 The research was made possible through a collaboration between several globally recognised institutions, including: 

• University of Cambridge (UK)

• Brigham and Women’s Hospital, Harvard Medical School (Boston, MA, USA)

• Boston Children’s Hospital, Harvard Medical School (Boston, MA, USA)

• Massachusetts Institute of Technology (Cambridge, MA, USA)

• University of Oxford (UK)

  
  

Their combined expertise was instrumental in the successful validation of this groundbreaking diagnostic tool.

 Traumatic brain Injury affects millions of people globally each year, ranging from mild concussions to severe neurological trauma. Timely and accurate diagnosis is essential for effective intervention. The new rapid GFAP test offers the potential to reduce unnecessary CT scans, streamline triage and emergency protocols, and ensure that patients receive appropriate care faster than ever before.

 Upfront Diagnostics remains committed to advancing diagnostic science through innovation and clinical collaboration. The company believes its GFAP test will revolutionise the way TBI is assessed, providing a long-needed, rapid, and accessible tool for clinicians at the front lines of care.

Story by Upfront Diagnostics